462 related articles for article (PubMed ID: 19241459)
41. Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease.
Abramowicz A; Gos M
Dev Period Med; 2014; 18(3):297-306. PubMed ID: 25182393
[TBL] [Abstract][Full Text] [Related]
42. Analysis of NF1 gene mutations in neurofibromatosis type 1 patients in Japan.
Hatta N; Horiuchi T; Fujita S
Biochem Biophys Res Commun; 1994 Feb; 199(1):207-12. PubMed ID: 8123014
[TBL] [Abstract][Full Text] [Related]
43. A de novo Alu insertion results in neurofibromatosis type 1.
Wallace MR; Andersen LB; Saulino AM; Gregory PE; Glover TW; Collins FS
Nature; 1991 Oct; 353(6347):864-6. PubMed ID: 1719426
[TBL] [Abstract][Full Text] [Related]
44. Neurofibromatosis type 1 gene mutations in neuroblastoma.
The I; Murthy AE; Hannigan GE; Jacoby LB; Menon AG; Gusella JF; Bernards A
Nat Genet; 1993 Jan; 3(1):62-6. PubMed ID: 8490657
[TBL] [Abstract][Full Text] [Related]
45. Mid-aortic syndrome with renovascular hypertension and multisystem involvement in a girl with familiar neurofibromatosis von Recklinghausen type 1.
Petrak B; Bendova S; Seeman T; Klein T; Lisy J; Zatrapa T; Marikova T
Neuro Endocrinol Lett; 2007 Dec; 28(6):734-8. PubMed ID: 18063929
[TBL] [Abstract][Full Text] [Related]
46. [Characterization of the neurofibromatosis type 1 gene and neurofibromin's role in cells].
Sakai A
Nihon Rinsho; 2000 Jul; 58(7):1426-9. PubMed ID: 10921317
[TBL] [Abstract][Full Text] [Related]
47. Alport syndrome. Molecular genetic aspects.
Hertz JM
Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
[TBL] [Abstract][Full Text] [Related]
48. Reproductive decisions after prenatal diagnosis in neurofibromatosis type 1: importance of genetic counseling.
Terzi YK; Oguzkan-Balci S; Anlar B; Aysun S; Guran S; Ayter S
Genet Couns; 2009; 20(2):195-202. PubMed ID: 19650418
[TBL] [Abstract][Full Text] [Related]
49. Constitutional NF1 mutations in neurofibromatosis 1 patients with malignant peripheral nerve sheath tumors.
Kluwe L; Friedrich RE; Peiper M; Friedman J; Mautner VF
Hum Mutat; 2003 Nov; 22(5):420. PubMed ID: 14517963
[TBL] [Abstract][Full Text] [Related]
50. Identification of NF1 mutations in both alleles of a dermal neurofibroma.
Sawada S; Florell S; Purandare SM; Ota M; Stephens K; Viskochil D
Nat Genet; 1996 Sep; 14(1):110-2. PubMed ID: 8782831
[TBL] [Abstract][Full Text] [Related]
51. NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype.
Pasmant E; Sabbagh A; Spurlock G; Laurendeau I; Grillo E; Hamel MJ; Martin L; Barbarot S; Leheup B; Rodriguez D; Lacombe D; Dollfus H; Pasquier L; Isidor B; Ferkal S; Soulier J; Sanson M; Dieux-Coeslier A; Bièche I; Parfait B; Vidaud M; Wolkenstein P; Upadhyaya M; Vidaud D;
Hum Mutat; 2010 Jun; 31(6):E1506-18. PubMed ID: 20513137
[TBL] [Abstract][Full Text] [Related]
52. Fifty-four novel mutations in the NF1 gene and integrated analyses of the mutations that modulate splicing.
Xu W; Yang X; Hu X; Li S
Int J Mol Med; 2014 Jul; 34(1):53-60. PubMed ID: 24789688
[TBL] [Abstract][Full Text] [Related]
53. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1.
Weiss B; Bollag G; Shannon K
Am J Med Genet; 1999 Mar; 89(1):14-22. PubMed ID: 10469432
[TBL] [Abstract][Full Text] [Related]
54. Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.
Biayna J; Mazuelas H; Gel B; Terribas E; Dumbovic G; Rosas I; Fernández-Rodriguez J; Blanco I; Castellanos E; Carrió M; Lazaro C; Serra E
Sci Rep; 2021 Feb; 11(1):3661. PubMed ID: 33574490
[TBL] [Abstract][Full Text] [Related]
55. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders.
Side L; Taylor B; Cayouette M; Conner E; Thompson P; Luce M; Shannon K
N Engl J Med; 1997 Jun; 336(24):1713-20. PubMed ID: 9180088
[TBL] [Abstract][Full Text] [Related]
56. Increased neurofibromatosis 1 gene expression in astrocytic tumors: positive regulation by p21-ras.
Gutmann DH; Giordano MJ; Mahadeo DK; Lau N; Silbergeld D; Guha A
Oncogene; 1996 May; 12(10):2121-7. PubMed ID: 8668337
[TBL] [Abstract][Full Text] [Related]
57. Antisense oligonucleotide therapeutics for iron-sulphur cluster deficiency myopathy.
Kollberg G; Holme E
Neuromuscul Disord; 2009 Dec; 19(12):833-6. PubMed ID: 19846308
[TBL] [Abstract][Full Text] [Related]
58. The effect of disease-associated HRPT2 mutations on splicing.
Hahn MA; McDonnell J; Marsh DJ
J Endocrinol; 2009 Jun; 201(3):387-96. PubMed ID: 19332451
[TBL] [Abstract][Full Text] [Related]
59. Analysis of CpG C-to-T mutations in neurofibromatosis type 1. Mutations in brief no. 129. Online.
Krkljus S; Abernathy CR; Johnson JS; Williams CA; Driscoll DJ; Zori R; Stalker HJ; Rasmussen SA; Collins FS; Kousseff BG; Baumbach L; Wallace MR
Hum Mutat; 1998; 11(5):411. PubMed ID: 10336779
[TBL] [Abstract][Full Text] [Related]
60. Disease-causing mutations improving the branch site and polypyrimidine tract: pseudoexon activation of LINE-2 and antisense Alu lacking the poly(T)-tail.
Meili D; Kralovicova J; Zagalak J; Bonafé L; Fiori L; Blau N; Thöny B; Vorechovsky I
Hum Mutat; 2009 May; 30(5):823-31. PubMed ID: 19280650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
